2016 Q4 Form 10-Q Financial Statement
#000114420416134410 Filed on November 14, 2016
Income Statement
| Concept | 2016 Q4 | 2015 Q3 | 2014 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $330.0K | $1.070M | $1.030M |
| YoY Change | -42.11% | 24.42% | 87.27% |
| % of Gross Profit | |||
| Research & Development | $320.0K | $1.500M | $1.640M |
| YoY Change | -61.45% | -4.58% | 92.94% |
| % of Gross Profit | |||
| Depreciation & Amortization | $20.00K | $20.00K | $30.00K |
| YoY Change | 0.0% | -33.33% | 50.0% |
| % of Gross Profit | |||
| Operating Expenses | $650.0K | $2.570M | $2.670M |
| YoY Change | -53.57% | 5.85% | 90.71% |
| Operating Profit | -$2.571M | ||
| YoY Change | 5.8% | ||
| Interest Expense | |||
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | $30.00K | -$30.00K | -$60.00K |
| YoY Change | 200.0% | -400.0% | -135.29% |
| Pretax Income | -$620.0K | -$2.600M | -$2.730M |
| YoY Change | -55.07% | 7.44% | 120.16% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$620.0K | -$2.603M | -$2.730M |
| YoY Change | -55.07% | 7.52% | 123.77% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$33.17K | -$140.7K | -$178.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 18.69M shares | 15.28M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q4 | 2015 Q3 | 2014 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $9.990M | $17.15M | $8.540M |
| YoY Change | -37.41% | 62.25% | 144.0% |
| Cash & Equivalents | $547.0K | $710.0K | $4.251M |
| Short-Term Investments | $9.440M | $16.44M | $4.290M |
| Other Short-Term Assets | $150.0K | $120.0K | $30.00K |
| YoY Change | 114.29% | 33.33% | 0.0% |
| Inventory | |||
| Prepaid Expenses | $117.0K | $52.00K | |
| Receivables | $310.0K | $820.0K | $1.010M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $10.44M | $18.09M | $9.598M |
| YoY Change | -37.81% | 62.88% | 115.88% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $297.0K | $268.0K | $313.0K |
| YoY Change | 9.59% | -0.74% | 21.32% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $322.0K | $333.0K | |
| YoY Change | 10.27% | 1565.0% | |
| Total Long-Term Assets | $330.0K | $268.0K | $313.0K |
| YoY Change | 13.01% | -8.53% | 11.79% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $10.44M | $18.09M | $9.598M |
| Total Long-Term Assets | $330.0K | $268.0K | $313.0K |
| Total Assets | $10.77M | $18.36M | $9.911M |
| YoY Change | -36.94% | 61.04% | 109.71% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $345.0K | $335.0K | $1.542M |
| YoY Change | -70.49% | -74.23% | 576.32% |
| Accrued Expenses | $150.0K | $2.308M | $1.347M |
| YoY Change | -90.0% | 181.46% | 53.59% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | ||
| YoY Change | |||
| Total Short-Term Liabilities | $860.0K | $2.838M | $3.113M |
| YoY Change | -70.87% | 18.25% | 133.71% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $0.00 | $120.0K | |
| YoY Change | -100.0% | -81.82% | |
| Total Long-Term Liabilities | $0.00 | $0.00 | $123.0K |
| YoY Change | -100.0% | -81.22% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $860.0K | $2.838M | $3.113M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $123.0K |
| Total Liabilities | $864.0K | $2.838M | $3.236M |
| YoY Change | -70.73% | 13.57% | 62.86% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$75.12M | -$68.76M | -$61.65M |
| YoY Change | 7.1% | 16.69% | 17.64% |
| Common Stock | $85.03M | $84.28M | $68.33M |
| YoY Change | 0.9% | 24.26% | 23.9% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $9.902M | $15.52M | $6.675M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $10.77M | $18.36M | $9.911M |
| YoY Change | -36.97% | 61.04% | 109.71% |
Cashflow Statement
| Concept | 2016 Q4 | 2015 Q3 | 2014 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$620.0K | -$2.603M | -$2.730M |
| YoY Change | -55.07% | 7.52% | 123.77% |
| Depreciation, Depletion And Amortization | $20.00K | $20.00K | $30.00K |
| YoY Change | 0.0% | -33.33% | 50.0% |
| Cash From Operating Activities | -$1.200M | -$2.530M | -$2.010M |
| YoY Change | -6.98% | 126.09% | 25.63% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $12.00K | -$70.00K |
| YoY Change | -100.0% | 600.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $790.0K | $1.950M | -$2.690M |
| YoY Change | -13.19% | -221.12% | -156.16% |
| Cash From Investing Activities | $790.0K | $1.940M | -$2.760M |
| YoY Change | -12.22% | -220.8% | -157.62% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | 0.000 | 50.00K |
| YoY Change | -100.0% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -1.200M | -2.530M | -2.010M |
| Cash From Investing Activities | 790.0K | 1.940M | -2.760M |
| Cash From Financing Activities | 0.000 | 0.000 | 50.00K |
| Net Change In Cash | -410.0K | -590.0K | -4.720M |
| YoY Change | 46.43% | -74.99% | -247.96% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.200M | -$2.530M | -$2.010M |
| Capital Expenditures | $0.00 | $12.00K | -$70.00K |
| Free Cash Flow | -$1.200M | -$2.542M | -$1.940M |
| YoY Change | -5.51% | 127.17% | 22.01% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
955000 | USD | |
| CY2016Q3 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-84000 | USD |
| CY2015Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
710000 | USD |
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
0 | USD | |
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
12409000 | USD | |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6675000 | USD |
| CY2015 | us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
108000 | USD |
| CY2015 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
835000 | USD |
| CY2015Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
732000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-3000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-420000 | USD |
| CY2015Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
287000 | USD |
| CY2016Q3 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
90000 | USD |
| CY2015Q3 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
0 | USD |
| CY2016Q3 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-1140000 | USD |
| CY2015Q3 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
552000 | USD |
| CY2015 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
109000 | USD |
| CY2015 | bcli |
Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
|
2000 | USD |
| CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8488000 | USD |
| CY2015 | bcli |
Exercise And Reissuance Of Warrants Value
ExerciseAndReissuanceOfWarrantsValue
|
12409000 | USD |
| CY2015 | bcli |
Exercise Of Liability Classified Warrants
ExerciseOfLiabilityClassifiedWarrants
|
145000 | USD |
| CY2015 | bcli |
Exercise Of Equity Classified Warrants
ExerciseOfEquityClassifiedWarrants
|
2333000 | USD |
| us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
121000 | USD | |
| us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
636000 | USD | |
| us-gaap |
Other Depreciation And Amortization
OtherDepreciationAndAmortization
|
55000 | USD | |
| us-gaap |
Other Depreciation And Amortization
OtherDepreciationAndAmortization
|
73000 | USD | |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | USD | |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
7000 | USD | |
| us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-940000 | USD | |
| us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
932000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-817000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-1207000 | USD | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
121000 | USD | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
108000 | USD | |
| bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-119000 | USD | |
| us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
636000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6117000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-4662000 | USD | |
| CY2016Q3 | us-gaap |
Other Depreciation And Amortization
OtherDepreciationAndAmortization
|
17000 | USD |
| CY2015Q3 | us-gaap |
Other Depreciation And Amortization
OtherDepreciationAndAmortization
|
26000 | USD |
| CY2016Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | USD |
| CY2016Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
171000 | USD |
| CY2015Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2530000 | USD |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
96000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
28000 | USD | |
| us-gaap |
Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
|
-5289000 | USD | |
| us-gaap |
Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
|
12151000 | USD | |
| bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
4000 | USD | |
| bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
2000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
5189000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-12181000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
14757000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
527000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-3541000 | USD | |
| us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | USD | |
| us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
130000 | USD | |
| CY2016Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
11000 | USD |
| CY2016Q3 | us-gaap |
Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
|
-299000 | USD |
| CY2016Q3 | bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
2000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
286000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
11000 | USD |
| CY2016Q3 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
0 | USD |
| CY2015Q3 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
0 | USD |
| CY2015Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-591000 | USD |
| CY2016Q3 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | USD |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4251000 | USD |
| CY2015Q3 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | USD |
| us-gaap |
Stock Issued1
StockIssued1
|
0 | USD | |
| CY2016Q3 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2015Q3 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2015Q3 | bcli |
Noncash Financing Activities
NoncashFinancingActivities
|
0 | USD |
| bcli |
Noncash Financing Activities
NoncashFinancingActivities
|
0 | USD | |
| bcli |
Noncash Financing Activities
NoncashFinancingActivities
|
130000 | USD | |
| CY2016Q3 | bcli |
Noncash Financing Activities
NoncashFinancingActivities
|
0 | USD |
| bcli |
Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
|
0 | USD | |
| bcli |
Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
|
2348000 | USD | |
| CY2016Q3 | bcli |
Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
|
0 | USD |
| CY2015Q3 | bcli |
Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
|
0 | USD |
| us-gaap |
Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
|
0 | USD | |
| us-gaap |
Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
|
0 | USD | |
| CY2016Q3 | us-gaap |
Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
|
0 | USD |
| CY2015Q3 | us-gaap |
Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
|
0 | USD |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
11193000 | USD |
| bcli |
Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
|
0.05 | pure | |
| bcli |
Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
|
P15Y | ||
| bcli |
Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
|
0.03 | pure | |
| us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P3M | ||
| CY2015 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P6M | |
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
46600000 | USD | |
| CY2009Q4 | us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
74667 | shares |
| CY2016Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
171000 | USD |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
667000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
955000 | USD | |
| CY2015Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
287000 | USD |
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2016-09-30 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2016 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
BRAINSTORM CELL THERAPEUTICS INC. | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001137883 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | ||
| dei |
Trading Symbol
TradingSymbol
|
BCLI | ||
| CY2016Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
18687987 | shares |
| CY2016Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2016Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18687987 | shares |
| CY2016Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18687987 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18643288 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18643288 | shares |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>D.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Use of estimates</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0px 0px 0px 85.05pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2014Q3 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-15 |
